Chris Triggle

Dr. Triggle obtained a PhD in Pharmacology from the University of Alberta in Edmonton, Canada where he studied the properties of non-innervated human placental and umbilical artery function. After postdoctoral work in the Department of Biochemical Pharmacology at the State University of New York in Buffalo and studies of neurotransmitter receptor-calcium channel coupling in smooth muscle he joined the Faculty of Medicine at Memorial University of Newfoundland (MUN), St John’s, Canada. At MUN he continued research work in smooth muscle pharmacology and vascular dysfunction in hypertension and, in 1983, was appointed Associate Dean of Basic Medical Sciences and University Research Professor. In 1990 Dr. Triggle re-established his research program in the Faculty of Medicine at the University of Calgary where he was appointed Head of the Department of Pharmacology & Therapeutics and the Alberta Heart & Stroke Chair in Cardiovascular Research and, in 1999, Associate Dean of Research (Medicine). During his tenure in Calgary Dr. Triggle served as the pre-clinical senior research consultant for Ciba Canada and later Novartis Canada and also as the President of the stem cell biotechnology company, Neurospheres. In 2004 Dr. Triggle became the Director of the Biotechnology Institute & Innovation Professor at RMIT University in Melbourne, Australia, where, as Chair of the Microvascular Research Group, he pursued studies of microvascular disease in diabetes. Dr. Triggle joined WCMC-Q faculty in 2007 as Professor of Pharmacology and also now holds the position of Assistant Dean for Admissions. Research in the area of vascular disease and diabetes continues through multiple collaborations.